Nektar Sells Movantik Rights for Up to $100M
Ticker: NKTR · Form: 8-K · Filed: Apr 17, 2024 · CIK: 906709
Sentiment: neutral
Topics: asset-sale, royalty-sale, pharmaceuticals
Related Tickers: NKTR
TL;DR
Nektar selling Movantik US rights for $70M upfront + $30M milestones. Deal closes Q2.
AI Summary
Nektar Therapeutics announced on April 17, 2024, that it has entered into a definitive agreement to sell its U.S. royalty rights for the blockbuster drug Movantik to Montrose Acquisition LLC for up to $100 million. The transaction includes an upfront payment of $70 million and potential milestone payments totaling $30 million, with the deal expected to close in the second quarter of 2024.
Why It Matters
This sale allows Nektar to monetize a key asset, potentially providing capital for future development or operational needs, while Montrose gains significant royalty streams from a commercialized drug.
Risk Assessment
Risk Level: medium — The risk is medium due to the contingent nature of the $30 million in milestone payments, which are not guaranteed.
Key Numbers
- $100M — Total Transaction Value (Maximum potential proceeds from the sale of U.S. royalty rights for Movantik.)
- $70M — Upfront Payment (Cash Nektar Therapeutics will receive immediately upon closing the deal.)
- $30M — Milestone Payments (Additional payments Nektar could receive if certain conditions are met.)
Key Players & Entities
- Nektar Therapeutics (company) — Seller of royalty rights
- Movantik (drug) — Royalty rights being sold
- Montrose Acquisition LLC (company) — Buyer of royalty rights
- $100 million (dollar_amount) — Total potential value of the transaction
- $70 million (dollar_amount) — Upfront payment for the royalty rights
- $30 million (dollar_amount) — Potential milestone payments
- April 17, 2024 (date) — Date of the announcement
- second quarter of 2024 (date) — Expected closing period for the transaction
FAQ
What specific U.S. royalty rights is Nektar Therapeutics selling?
Nektar Therapeutics is selling its U.S. royalty rights for the drug Movantik.
Who is the buyer of these royalty rights?
The buyer is Montrose Acquisition LLC.
What is the total potential value of this transaction?
The total potential value is up to $100 million.
When is the transaction expected to close?
The transaction is expected to close in the second quarter of 2024.
Are there any conditions attached to the $30 million in potential payments?
Yes, the $30 million represents potential milestone payments, implying they are contingent upon certain events or achievements.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-04-17 17:03:35
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
- $1.00 — th the minimum bid price requirement of $1.00 per share (the "Minimum Bid Price Requi
Filing Documents
- ea0204090-8k_nektar.htm (8-K) — 23KB
- 0001213900-24-033856.txt ( ) — 190KB
- nktr-20240417.xsd (EX-101.SCH) — 3KB
- nktr-20240417_lab.xml (EX-101.LAB) — 33KB
- nktr-20240417_pre.xml (EX-101.PRE) — 22KB
- ea0204090-8k_nektar_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, on May 26, 2023, Nektar Therapeutics (the "Company") received a notice from the Nasdaq Listing Qualifications Department (the "Staff") stating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share (the "Minimum Bid Price Requirement") for continued listing on the Nasdaq Global Market because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share or greater for 30 consecutive business days. The Company was given an initial 180 calendar day period, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. On November 24, 2023, the Company received another notice from the Staff stating that the Company was eligible for an additional 180 calendar day period, or until May 20, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company's common stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market at the opening of business on November 28, 2023. On April 17, 2024, the Company received a letter from the Staff notifying the Company that it has regained compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market. To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: April 17, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2